AnalystsInsight

Debanjana Chatterjee (JonesTrading): Analyst Track Record and Price‑Target Accuracy

Debanjana Chatterjee is one of the top‑ranked analysts in Exent’s 7‑year backtest. What Debanjana covers, how Debanjana’s ratings lean, how fast price targets were reached and the ratings from before the last 30 days; the full record and the newest calls are members‑only.

Reviewed by:David, Senior AnalystPublished Oct 12, 2026Updated Oct 20, 20262 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+4 new ratings (stocks members‑only)

Key takeaways

Debanjana Chatterjee ranks among the top 50 healthcare analysts in Exent’s ranking, scored on a 7‑year backtest.
The exact rank, price‑target hit rate and live calls are members‑only in Exent Gems.
Most‑covered stocks: EYPT, SYRE, NTLA, IRD.
In the past year Debanjana’s ratings were 93% Buy, 7% Hold and 0% Sell.

In this article

Debanjana Chatterjee’s track record at a glance
How fast price targets were reached
Stocks Debanjana Chatterjee covers most
Debanjana Chatterjee’s latest ratings
How Exent scores analysts

Debanjana Chatterjee’s track record at a glance

Debanjana Chatterjee of JonesTrading ranks among the top 50 healthcare analysts in Exent’s ranking, with a focus on healthcare. The top of the ranking is what Exent Gems follows, so Debanjana’s exact rank, hit rate and live calls are for members.

Metric	Debanjana Chatterjee	All analysts
Exent rank		—
Price‑target hit rate		52.4%
Calls up after 12 months		64.0%
Median 12‑month return of calls		+13.4%
Median days to hit target		91 days
Stocks covered	19	—

Unlock the full record in Gems

How fast price targets were reached

Time to reach the target	Debanjana Chatterjee
Under 30 days	12.8%
30–90 days	22.1%
90–180 days	30.2%
Over 180 days	34.9%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Debanjana Chatterjee covers most

EYPT · SYRE · NTLA · IRD · TVRD · SGMT · ABSI · PHVS

In the past year Debanjana’s ratings were 93% Buy, 7% Hold and 0% Sell.

Debanjana Chatterjee’s latest ratings

Date	Stock	Action	Rating	Price target
Sep 20, 2026	CTNM	Reiterated: Buy	Buy	$24.00
Sep 15, 2026	HYFT	Reiterated: Buy	Buy	$5.00
Sep 15, 2026	TVRD	Reiterated: Buy	Buy	$10.00
Sep 15, 2026	CTNM	Reiterated: Buy	Buy	$24.00
Sep 9, 2026	IRD	Reiterated: Buy	Buy	$10.00
Sep 9, 2026	PHVS	Reiterated: Buy	Buy	$65.00
Sep 2, 2026	CTNM	Reiterated: Buy	Buy	$26.00
Aug 28, 2026	ATHE	Reiterated: Buy	Buy	$16.00
Aug 28, 2026	ARMP	Reiterated: Buy	Buy	$20.00
Aug 28, 2026	PHVS	Reiterated: Buy	Buy	$52.00
Aug 28, 2026	IRD	Reiterated: Buy	Buy	$10.00
Aug 26, 2026	SYRE	Reiterated: Buy	Buy	$121.00

Sep 20, 2026
Stock
CTNM
Action
Reiterated: Buy
Rating
Buy
Price target
$24.00
Sep 15, 2026
Stock
HYFT
Action
Reiterated: Buy
Rating
Buy
Price target
$5.00
Sep 15, 2026
Stock
TVRD
Action
Reiterated: Buy
Rating
Buy
Price target
$10.00
Sep 15, 2026
Stock
CTNM
Action
Reiterated: Buy
Rating
Buy
Price target
$24.00
Sep 9, 2026
Stock
IRD
Action
Reiterated: Buy
Rating
Buy
Price target
$10.00
Sep 9, 2026
Stock
PHVS
Action
Reiterated: Buy
Rating
Buy
Price target
$65.00
Sep 2, 2026
Stock
CTNM
Action
Reiterated: Buy
Rating
Buy
Price target
$26.00
Aug 28, 2026
Stock
ATHE
Action
Reiterated: Buy
Rating
Buy
Price target
$16.00
Aug 28, 2026
Stock
ARMP
Action
Reiterated: Buy
Rating
Buy
Price target
$20.00
Aug 28, 2026
Stock
PHVS
Action
Reiterated: Buy
Rating
Buy
Price target
$52.00
Aug 28, 2026
Stock
IRD
Action
Reiterated: Buy
Rating
Buy
Price target
$10.00
Aug 26, 2026
Stock
SYRE
Action
Reiterated: Buy
Rating
Buy
Price target
$121.00

Ratings from the last 30 days are members‑only in Exent Gems, with the stocks where several top‑ranked analysts agree; older ratings are shown in full.

See the latest ratings in Gems

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

Exent Gems shows Debanjana Chatterjee’s full record and latest ratings, without the 30‑day delay.
Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

See this week’s Gems

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring, Debanjana Chatterjee ranks among the top 50 healthcare analysts in Exent’s ranking, based on a 7-year backtest of price-target hit rate, returns after calls and number of ratings. The exact rank, hit rate and live calls are members-only in Exent Gems (exent.ai/radar). Past accuracy does not guarantee future accuracy.

Debanjana Chatterjee’s price-target hit rate is part of the members-only record in Exent Gems (exent.ai/radar). For comparison, the average analyst’s price targets were reached 52.4% of the time.

Debanjana Chatterjee (JonesTrading) covers 19 stocks, mostly in healthcare. The most frequently rated are EYPT, SYRE, NTLA, IRD, TVRD.

: .-++++=: .-=+**+-. .:=+*#*=:..::-+##*+-:. .-+**+++=:. .:::-=+**********++===++***+++*###*+=--:. .:==+*#*+-:..::-+##*+-:. :=**++=: .-=+**+-. .:=+*#*-...: . -++*+=: .:=+**+-. .:-+*#*=:..::=+##*=-:...:=***++=:. .:-=+*###*++==--:::::::...:---==+*##**++=-. .:-=+###*=-:...-+**++=: :=++*+-. :-=***=:..:-=*##+-..: :=+*++-. :=++*+=. :-=*#*+-..::=+##*=-:...-+*#*+=-. :-=+*###*+=--:. .... .::..:-=+++****=-:..::-=*#*+=-: .-=++++=. .-=+**+-...:=+##*=:.::-+##*=::. .-++++=: .-=+**=: .-=+*#+-...:-+##*=-::.:-+##*+=:. .-=++***+=-:::.. ..:-----:::::::. .:-=+*###*=-:.. :=+**++-. .-=+**+-. .:-+*##+:..:-=*##+-:..:=*#*+-:. :=+*++-. :=+**+-. .:=+*#*-...:-+*##+-:.::-+##*=-:. :=++**++-:...::::-==+++++****++===-:....:::-+*#*+==:. .-=+**+-. .:-=*##+-:.::-+##*=::.:-+##*=-:..-+#*+=:. .-++++=: .-++**=: :-=***=:..:-=*##+-:.::-+##*=-:...:=***++-: .:-==*###**+**####*******+=-::...:-+**++=-. :-=+##*-:..:-+###+-:..:=*#*+-:..:=*#*=-: :=**+=-. :=++++-. :=+**+-. .-=+**+-...-=+##*-:.::-+##*=-:...-+***+=-. .:-=+*####*+==========++*###*+=-:. .-=+***+-...:-=*##+-::.:-*##+=-:..-+#*+=-. .-+**+=: .-++++=: :=+*+=: .-=+**=: :-+***=: .:-+*#*=:..:-+###+-::.:-+##*=-:. .-=++****+---::. .::::--+****++=-. .:-+*##+-::.:-+##*=-:..:=*#*+-: .=**++-. :=+*++-. :=+**+: -++*+=. :=+**+-. .-=+**+-..:-=*##+-..:-=*##+-::.:-+##*=-:. :=+++*++-:...:.. ...:.. .:-=+**#*=:..::-+##*+-:...-+#*+=-. -+**+=: .-++*+=: .-++*+=. :=+**+- =+**+- .-=+**=: :-=*#*=:..:-+*#*=:.::-+##*=::.:-+##*=-:. .-+**++=-: .::---====---:. .::-=*##*=-:...-+##+=-: :=+*++-. .=++++-. :=+**+-. .-=+**+: .:-=*#*= =+**=: :-=***=. .:=+*#+-..:-=*##+-..:-=*##+-:.::=*##+-:...-+**++=:. .:-==+*###*+++++=-:..:::=*##*=-:. .-+**+=: -=+*+=: .-=+**=: :-=*#*=. .:=+*#+-..:-=*##+ =+**=. .:=+**+-. .-=*##+:..:-+*#*=:.::-+##*-::::=*##+=::..-+##*=-: :-=++*###**+++*###*=-::. .-+**+=-. :=++*+=. :-+**+-. .:=+*#+-..:-=*##+:..:-+##*=:.::=*##+ +**+-. .-=+**+:..:-+*#*=:..:=+##+-:.:-=*##+-:.:-+##*=-:..:+*#*=-:. .:=++***+=------=+*##*+=-. .-++*+=: .-=+**+: .-=*#*=:..:-+*#*=:.::=*##+-:.:-+##*=::.:-*##+ +**+-. :-=*#*=:..:-+##*-..:-=*##+-:.:-+##*=::.:-*##+-:..:=*#*+-:. .-+**++=-:. ..:...:-=+*++=-. :-+***=. .:-+*#*-...:=+##+-..:-=*#*=::::-+##+-::.:=*#*=-:..-+##+ +*#+:..:-+*#*=:..:=*##+-:.:-+##*=::::-*##+-:..:=*#*=-:..:+##+=-. .:+**++-: .::::. :-++**+:. .-=+##+:..:-=*#*=:..:-+##*-::::=*##+-:.:-+##*=::.:=*#*+-:..:+##+ *##+:..:-+##*-:.::=*##+-:::-+##*=::.:=*##+-:..-+##*=-...-*#*+-:. .=***+-: :-====-: .:-+*#*=:..:-+##*-:.::=*##+-:.:-+##*=::.:=*##+-:..:+##+=-...-*#*+-:. :+**+ *##=:..:-+##*-:.::=*##=-:.:-+##+-:..:=*#*=-:..-+##+=:. :=*#*=-: :+**+=:. .-=++**#*+-..:-=*##+-:.:-+##*=::.:=*##+-:..:+##*=-:..-*#*+-:..:+**+=-. .-***+-: :=**+ *##=::::-+##+-::::=##*=-:.:-*##+-:..:=##*=-:..-+#*+-:. :=**+=-. .-+**+=: :=+*+++##*=::::=*##+-:.::+##*=-:.:-*##+-:..:+##*=-...-*#*+-: :=**+=-. .-+*++-. :=+*+ ##*=::.:-*##+-:..:=##*=-:..-*#*+-:..:=*#+=-. .-+**+-: :=**+=-. .-+*++=. :=++++*##*=::.:=*##+-:..:+##*=-:..-*#*+-:..:+**+=-. .-***+-: :=**+=: .-+*++-. :=+++ ##*=-:..-*##+-:..:=*#*=-...-+#*+-:. :=**+=-. .-+**+=: .=+*+=-. -=+*+=: .-=+*###*=-:..:=*#*=-:..-+##+=:...=*#*=-: :+**+=:. .-+*++-. :=**+=: .-++++-. :=+** ##*=-:..-+#*+-:. :=**+=-. .-+**+=: .=**+=-. :++++=: .-++*+-. :=+**+-. .:--=++=-:::.:-*##+=:...-*#*+-:. :=**+=-. -+**+=: .=+*+=-. :=+++=: .-++*+-. .-=+** *#*=-: .-+**+=:. .=**+=-. :+**+=: .-++++-. :=+**+: .-=+**=: :-=+##+-:...........::-+##*=-:..:=*#*=-. :+**+=:. .-+*++-. :=+*+=- .-++*+=. :=+**+- .-=+** ***=-. :+**+=: .-+*++-. :=+++=: .-=+*+=. :-+**+-. .:=+*#*-:..:-+*##*=--:. .:--=*##*=-:...-*#*+=:. .-+**+-: .=+*+=-. :=+*+=: .-++*+-. :=+**+: :-=*** +*++-. :=+*+=: .-++*+=. :=+**+-. .:=+**+: :-=*#*+:..:-=*##+-::.:-=*##*+==------==+*##*=-:...-+##+=-. :+**+=-. :++*+=: .-++*+=. :=+**+-. .-=+**=: .:-+*#* ++++=: :=++*+-. .:=+**=: .-=***=. .:-+*#*-...:=+##*=::::-+##*+-:.. .-++++**##***++**#*+-::..:-+##*=-:. .=***+=: .-+*++-. :=++*+-. .-=+**+: :-=*#*=. .:=+##+ =+*+=: .-++**=. .:=+**+-. .-=+##+-..:-=*##+-:.:-=*##+-:...-+##*+=:. .:-==+*###**++++=-:..:::=*##*=-:. .-+**+=:. :=+*+=: .-=+**=: .-=***=. .:=+*#+-..:-=*##+ =+**+-. .-=+**=:..:-+*#*=:..:-+##*=:.::-+##*=::..-+##*=-:. .-++*+++-: .::::--====--:. .::-+*##*=-:. .-+**+=-. :=+*++-. :=++*+-. .:=+**+-. .-=+##+:..:-+*#*= -+*#*=...:=+##+-..:-=*##+-:.:-=###+-:..:=*#*+-:. .-+**+=-. .:=++*#*+-:::.. .::.. .:--=+###*=-:...-+**+=-: .-+*++=: .-=+**=: .-=+**=: .:-+*#*=:..:=+##*- -=*##=:..:-+##*=::::-+##*=::..-*##+=-. .-+**+=-. .-++**+-. .:-=*###*+=--:.....:::..:--=++*##*+-::..:-+##*=-: .-+**+=-. :=+**+-. .:=+*#+-...-=+##+-..:-=*##+- :=*##+-::::=*##+-:..:=*#*=-:. :=***+-: .-++++=-. :-=+*#*=:..:::-=****++*+++======++********=-:..::-=*##*=-:. .-+**++-. .-++**=: :-=***=:..:-=*#*=:..:-+##*=: :-+##*=-:..-+##+=-. .-+**+=:. :++*++-. :-++**+-. .:-=*##*+--:. .:==++*####**++*####**++==:. .:--+###*=-:. .-+**++-: .-=+**+: .-=+*#+-...-=+##+-..:-=*##+-: .:=*#*=-:. :=**+=-: :=+*++-. .-=+**+:. .:-+*##+-:::::=+##*+=-:. .:--==+**++++****+==--: :--=*###+=-:...-+**++-: .-=+**+-. :-+***=:..:-+*#*=:..:-+##*=:: .-+**+=:. .-+**+=: .-=+**+-. .:-+*#*+:..::-+###+=-:. .:=+***++=-:........::-----::::::.. :-==+*##*=-::..:=*#*+=-: .:=++++-. :-=+**+:..:-=*##+-..:-=*##+-:: :=+*++-. :=++*+=. :-=***+-..::=+##*=-::.:-+*#*+=-: :-=+*###*+=--:. ..:. .:::::-=+++****=-:..::-=*##+=-:. .-=+*++=: .-=+**+-. .:=+##*=:.::-+##*=::. .-=+**=: .-=+**+-...:-+##*=-::::=*##*=-:. .:=+*+++=:. .::-=+*##**++==--::::::...::---=+**#**+++=:. ..:-=+###+=-:. .-+**++=: .-=+**+-. .:-+*#*=:..:-=*##+-::: . :-+***=:..:-=*##+-:.::=*##*=-:..:-+**+=-: :-=+*#*+=:::...:-=++++*###**++=+++++++++**###*+==-:. .:-=+*##*+-::...-+**++-: .:=+**+=. :-=*##+-..::=*##*-::.:

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.

What changed since Oct 12

Key takeaways

Are Analyst Price Targets Accurate? 7 Years of Data

How to Follow Wall Street Analysts the Smart Way: Track Records, Not Headlines

What Are Exent Gems? Top‑Analyst Agreement Explained